Pamiparib for Consolidation Treatment of Unprogressed LS-SCLC After Concurrent Chemoradiotherapy
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This study is a prospective, single-arm, phase II clinical trial, with 1-year PFS as the
endpoint, to evaluate the efficacy and associated toxicity of Pamiparib as single-agent
consolidation treatment in patients with limited-stage small cell lung cancer(LS-SCLC)
patients who have not progressed following platinum-based concurrent chemoradiotherapy(cCRT)
.